Wound Care Biologics Market size was over USD 2.7 Billion in 2023 and is expected to cross USD 6.7 Billion by the end of 2036, growing at more than 9.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of wound care biologics is assessed at USD 3.2 Billion.
The rising cases of chronic wounds such as ischemic ulcers and foot ulcers among diabetic patients are driving the market growth. According to a 2023 report by the Journal of the American Medical Association (JAMA), annually 18.6 million people worldwide suffer from foot ulcers with 1.6 million cases reported in the United States.
Significant advancements in clinical wound management and their pathophysiology, coupled with ongoing biomedical innovations have resulted in a shift from invasive skin grafting techniques to dermal fibroblasts. Several pharmaceutical companies are focused on the research and development of cutting-edge biologics to diversify their product offerings. For instance, in June 2021 Mallinckrodt launched StrataGraft, a FDA-approved allogeneic cellularized scaffold. It consists of dermal fibroblasts in murine collagen and allogeneic cultured keratinocytes that eliminate the need for autografting in chronic burn patients.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
9.1% |
|
Base Year Market Size (2023) |
USD 2.7 billion |
|
Forecast Year Market Size (2036) |
USD 6.7 billion |
|
Regional Scope |
|
Wound Type (Ulcers, Surgical and Traumatic, Burns)
Ulcers segment is expected to capture wound care biologics market share of over 45% by 2036 owing to the rising incidence of chronic venous leg ulceration among people suffering from varicose veins. According to a study published by the Journal of Vascular Surgery in 2023, around 40% of the population globally has varicose veins, one of the most common chronic venous illnesses. Venous leg ulcers impact approximately 1% to 2% of the population, with the prevalence rising to 4% in individuals over 65.
Chronic ulcers, such as diabetic foot ulcers and venous ulcers, are a major health concern worldwide. Advanced therapeutics such as negative pressure wound therapy (NPWT) promotes the healing of these complicated and resistant wounds. Such treatments reduce hospital time and facilitates quicker transitions to outpatient care settings. The efficacy of wound care biologics in accelerating ulcer closure, lowering infection risks, and improving overall patient outcomes caters to market expansion.
Product (Biologic Skin Substitutes, Topical Agents)
The biologic skin substitutes segment is estimated to expand at a staggering CAGR through 2036. The major factor in the expansion of the segment is the rising number of burn and trauma cases worldwide.
Burns due to fire, heat, or hot substances are the fourth most common form of civilian trauma worldwide, after road traffic accidents, falls, and interpersonal violence. It is estimated that between 7 and 12 million people sustain burn injuries for which medical attention is required. Biologic skin substitutes are therefore, in huge demand due to their ability to accelerate wound closure, reduce scarring and improve overall wound healing.
End-user (Hospitals, Ambulatory Surgery Centers (ASCs), Burn Centers, Wound Clinics)
In wound care biologics market, hospitals segment is projected to hold revenue share of over 32% by the end of 2036. Hospitals remain the foremost sites for patients seeking wound treatment, particularly those that are severe or chronic. Hospitals have wound-care units with qualified health professionals who are skilled at using biologics to aid in proper wound healing and improve patient outcomes. High patient football and the expanding demand for improved wound care treatments in hospital settings add to the segment growth.
Our in-depth analysis of the global market includes the following segments:
|
Product |
|
|
Wound Type |
|
|
End-User |
|
North American Market Statistics
North America region in wound care biologics market is anticipated to account for revenue share of around 45.1% by 2036. This rise is poised to be encouraged by a growing number of wound care procedures. As a consequence, wound care biologics are expected to be a growing business, which encompasses topical treatments and skin grafts composed of bioengineered cells. Particularly, in 2022, more than 12,880,540 wound dressing procedures were carried out over North America.
One of the main causes of unintended death in the United States is burns, which is likely to augment market demand for wound care biologics. According to the American Burn Association’s Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS), there are approximately 30,000 burn admissions per year (weighted estimates), representing 88.5 admissions per million lives per year.
In Canada, the market for wound care biologics is anticipated to expand since the prioritization of wound treatment is becoming more widely recognized among Canadian healthcare institutions.
European Market Analysis
The Europe region is estimated to account for the second-largest revenue share in the wound care biologics market through 2036. Majority of European nations now have universal health coverage, making the health care industry one of the fast-growing regions in the world. More than 55% of prescription drug expenditures in the EU are paid for by mandatory or governmental insurance programs.
In Germany, a new wound dressing called Epicite Balance was introduced by JeNaCell in June 2023, an Evonik business, using hydro polymer called biosynthetic cellulose for creative uses in medical devices. he dressing is especially well-suited and adapted for the management of chronic wounds which impact around 1% of people in developed nations, particularly elderly patients.
Also, more than 20% of Italians out of the country's total population are said to suffer from chronic ulcers, leading to market expansion.
Numerous important companies in the wound care biologics sector are implementing several tactical measures and are constantly collaborating, expanding, making agreements, and taking part in joint ventures to fortify their positions in the industry.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?